肿瘤药学2025，Vol.15Issue(5)：572-581,10.DOI:10.3969/j.issn.2095-1264.2025.05.02
驱动基因阴性晚期NSCLC治疗新药物新方向
New drug and new direction for the treatment of advanced NSCLC with negative driver genes
摘要
Abstract
Lung cancer remains the foremost cause of cancer-related mortality worldwide,with approximately 40％of adenocarcinoma cases lacking identifiable driver genes and effective targeted therapies.Consequently,chemotherapy,im-mune checkpoint inhibitors and their combination regimens constitute the primary therapeutic approaches.In recent years,immunotherapy has markedly enhanced patient survival rates and has been established as a standard first-line treatment.However,issues of primary resistance remain significant.Current research has increasingly focused on novel immune checkpoints and bispecific antibodies,which aim to reverse the immunosuppressive tumor microenvironment.Furthermore,the combination treatment strategy of immunotherapy plus anti-angiogenesis and antibody-drug conjugates has demonstrat-ed superiority over traditional regimens.In the area of technological innovation,emerging biological treatment modalities,including personalized vaccines,oncolytic viruses and CAR-T cell therapy,have shown promising antitumor activity in ad-vanced clinical trials.Future efforts should prioritize the elucidation of resistance mechanisms,the identification of bio-markers,and the implementation of multidisciplinary comprehensive management to further refine and optimize the thera-peutic landscape.关键词
非小细胞肺癌/驱动基因阴性/免疫治疗/免疫检查点抑制剂Key words
Non-small cell lung cancer/Driver gene negative/Immunotherapy/Immune checkpoint inhibitor分类
医药卫生引用本文复制引用
WANG Zhi,DONG Xiaorong..驱动基因阴性晚期NSCLC治疗新药物新方向[J].肿瘤药学,2025,15(5):572-581,10.基金项目
国家自然科学基金面上项目(82273323). （82273323）
